United States of America (Press Release) November 26, 2007 --
UK CRO Chiltern International (Slough, Berkshire) has acquired the independent US CRO Clinical Trial Management Services. Terms were not disclosed.
Established in 1989 by Dr Robert Vann, and Ben Essary, CTMS conducts clinical trials in a variety of therapy areas, specialising in respiratory, gastro-intestinal, central nervous system, infectious disease and ophthalmology. The company employs 190 people and has 36,000 sq ft of office space at its headquarters in Bristol, Tennessee, and in Winston-Salem, North Carolina.
John Vann, previously president and CEO of CTMS, has assumed overall leadership of Chiltern’s US operations, becoming executive vice-president Americas, effective October 30th. Dr Robert Vann has retired. From February 2008, CTMS will be known as Chiltern.
“The acquisition of CTMS significantly increases our presence and expertise within the US and strengthens Chiltern’s position as a global CRO,” said Chiltern CEO Glenn Kerkhof. “Detailed planning for the integration of our operations is under way and we are very confident of a smooth transition.” Submitted by www.jobs4dd.com, a niche online recruitment site for the clinical trial and drug development sectors. Latest news and jobs in the industry are listed on a daily basis. Latest international clinical research jobs, CRM jobs, regulatory affairs jobs, data management jobs, statistician jobs, pharmacovigilance jobs and many more vacancies are listed on the www.jobs4dd.com website. Visit our news archive section at www.jobs4dd.com/news-archive.php
Established in 1989 by Dr Robert Vann, and Ben Essary, CTMS conducts clinical trials in a variety of therapy areas, specialising in respiratory, gastro-intestinal, central nervous system, infectious disease and ophthalmology. The company employs 190 people and has 36,000 sq ft of office space at its headquarters in Bristol, Tennessee, and in Winston-Salem, North Carolina.
John Vann, previously president and CEO of CTMS, has assumed overall leadership of Chiltern’s US operations, becoming executive vice-president Americas, effective October 30th. Dr Robert Vann has retired. From February 2008, CTMS will be known as Chiltern.
“The acquisition of CTMS significantly increases our presence and expertise within the US and strengthens Chiltern’s position as a global CRO,” said Chiltern CEO Glenn Kerkhof. “Detailed planning for the integration of our operations is under way and we are very confident of a smooth transition.” Submitted by www.jobs4dd.com, a niche online recruitment site for the clinical trial and drug development sectors. Latest news and jobs in the industry are listed on a daily basis. Latest international clinical research jobs, CRM jobs, regulatory affairs jobs, data management jobs, statistician jobs, pharmacovigilance jobs and many more vacancies are listed on the www.jobs4dd.com website. Visit our news archive section at www.jobs4dd.com/news-archive.php

UK CRO Chiltern International (Slough, Berkshire) has acquired the independent US CRO Clinical Trial Management Services. Terms were not disclosed.
Email
Print
SPAM
USER COMMENTS



